kabutan

Chordia Therapeutics Inc.(190A) Summary

190A
TSE Growth
Chordia Therapeutics Inc.
106
JPY
-5
(-4.50%)
Dec 12, 3:30 pm JST
0.68
USD
Dec 12, 1:30 am EST
Result
PTS
outside of trading hours
106
Dec 12, 11:43 pm JST
Summary Chart Historical News Financial Result
PER
PBR
3.06
Yield
ー%
Margin Trading Ratio
531.43
Stock Price
Dec 12, 2025
Opening Dec 12, 9:00 am
111 JPY 0.71 USD
Previous Close Dec 11
111 JPY 0.71 USD
High Dec 12, 9:57 am
132 JPY 0.84 USD
Low Dec 12, 11:29 am
105 JPY 0.67 USD
Volume
11,364,800
Trading Value
1.33B JPY 8.53M USD
VWAP
116.95 JPY 0.75 USD
Minimum Trading Value
10,600 JPY 68 USD
Market Cap
7.44B JPY 0.05B USD
Number of Trades
3,284
Liquidity & Number of Trades
As of Dec 12, 2025
Liquidity
Slightly High
1-Year Average
933
1-Year High Jan 10, 2025
22,735
Margin Trading
Date Short Interest Long Margin Positions Ratio
Dec 5, 2025 0 4,432,600
Nov 28, 2025 0 4,232,300
Nov 21, 2025 0 4,215,800
Nov 14, 2025 0 4,587,600
Nov 7, 2025 0 4,500,600
Company Profile
Chordia Therapeutics Inc. engages in the development of cancer therapeutics targeting RNA regulation stress.
Sector
Pharmaceuticals
Chordia Therapeutics Inc. is a drug discovery venture company specializing in the research and development of novel anti-cancer drugs targeting RNA regulation stress. The company has multiple pipelines including CLK inhibitors, MALT1 inhibitors, and CDK12 inhibitors, aiming to create groundbreaking first-in-class pharmaceuticals. Clinical trials are currently underway for acute myeloid leukemia, ovarian cancer, and other indications. Chordia Therapeutics actively promotes collaborative research and licensing partnerships with universities, public institutions, and pharmaceutical companies to achieve efficient drug discovery operations. The company is also expanding its partnering strategy, as exemplified by the licensing agreement for MALT1 inhibitors with Ono Pharmaceutical Co., Ltd.